Vermillion Q4 Revenues Spike 45 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market on Thursday that its fourth quarter revenues grew 45 percent year over year on an increase in revenues generated by its OVA1 ovarian cancer test.

For the three months ended Dec. 31, 2013, the Austin, Texas-based company recorded $1.6 million in total revenues, up from $1.1 million in the year-ago period. Product revenues, comprised of OVA1 sales, rose to $1.5 million from $1.0 million, while licensing revenues were flat at $113,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.